Preparations with influence on the respiratory system and antiallergic

- 1. Determine the indications for antitussive drugs.
- 2. Determine the pharmacodynamic effects of acetylcysteine.
- 3. Determine beta-adrenomimetics as ultralong-acting bronchodilators.
- 4. Determine the therapeutic benefits of beta-adrenomimetics in bronchial asthma.
- 5. Determine the side effects of inhaled beta-adrenomimetics.
- 6. Determine M-cholinoblockers as ultralong-acting bronchodilators.
- 7. Determine the therapeutic benefit of M-cholinoblockers in bronchial asthma.
- 8. Determine the indications of M-cholinoblockers as bronchodilators.
- 9. Determine the inhaled glucocorticoids used in bronchial asthma.
- 10. Determine the therapeutic benefit of glucocorticoids in bronchial asthma.
- 11. Determine the side effects of inhaled glucocorticoids as bronchodilators.
- 12. Determine the therapeutic benefit of methylxanthines in bronchial asthma.
- 13. Determine the adverse reactions of methylxanthines as a function of concentration.
- 14. Determine the indications of methylxanthines.
- 15. Determine the antiallergic drugs used in anaphylactic shock.
- 16. Determine H1-antihistamines of the III-rd generation.
- 17. Determine H1-antihistamines of the II-rd generation.
- 18. Determine the pharmacodynamic effects of H1-antihistamines.
- 19. Determine the indications of H1-antihistamines with antiallergic purpose.
- 20. Determine the side effects of H1-antihistamines.
- 21. Determine the effects of epinephrine in anaphylactic shock.
- 22. Determine the effects of glucocorticoids as antiallergic
- 23. Determine the indications of glucocorticoids as antiallergic.
- 24. Determine the indications of mast cell degranulation inhibitors.
- 25. Determine the drugs used in asthma attacks.

Preparations with an influence on the cardiovascular system and diuretics

- 1. Determine the particularities of the antiarrhythmic effect of drugs from group1A.
- 2. Determine the particularities of the antiarrhythmic effect of drugs from group1B.
- 3. Determine the indications of antiarrhythmic drugs from group 1B.
- 4. Determine the particularities of the antiarrhythmic effect of beta-adrenoblockers.
- 5. Determine the particularities of the antiarrhythmic effect of calcium channel blockers.
- 6. Determine the particularities of the antiarrhythmic effect of amiodarone.
- 7. Determine the indications for amiodarone.
- 8. Determine the effects of cardiac glycosides on the heart.
- 9. Determine the electrocardiographic changes induced by therapeutic doses of cardiac glycosides.
- 10. Determine the clinical picture of poisoning with cardiac glycosides.
- 11.Determine the drugs used in cardiac glycoside poisoning.
- 12. Determine the pharmacokinetic characteristics of digoxin.
- 13. Determine the dosing principles of cardiac glycosides.
- 14. Determine the peculiarities of the antianginal effect of nitrates at the systemic level.
- 15. Determine the adverse reactions of nitrates.
- 16. Determine the peculiarities of the antianginal effect of beta-adrenoblockers.
- 17. Determine the peculiarities of the antianginal effect of calcium channel blockers.
- 18. Determine the drugs used in attacks of angina pectoris.
- 19. Determine direct-acting factor Xa antagonist anticoagulants.
- 20. Determine the groups of antiplatelet drugs.

- 21. Determine the clinical effects characteristic of standard heparin.
- 22. Determine the peculiarities of the anticoagulant effect of low molecular weight heparins.
- 23. Determine the particularities of the antiplatelet effect of acetylsalicylic acid.
- 24. Determine the indications for heparin.
- 25. Determine the indications of antiplatelet agents.
- 26. Determine the direct thrombin antagonist anticoagulants.
- 27. Determine the indications of fibrinolytics with indirect action.
- 28. Determine the adverse reactions of standard heparin.
- 29. Determine the indications of synthetic antifibrinolytics.
- 30. Determine the peculiarities of the hemostatic effect of vitamin K agents.
- 31. Determine the groups of neurotropic antihypertensive drugs.
- 32. Determine the antihypertensive drugs with influence on the renin-angiotensin-aldosterone system.

33. Determine the indications of alpha-2-adrenomimetics and centrally acting imidazoline receptor agonists.

- 34. Determine the peculiarities of the antihypertensive effect of beta-adrenoblockers.
- 35. Determine the particularities of the antihypertensive effect of calcium channel blockers.
- 36. Determine the particularities of the antihypertensive effect of angiotensine-converting enzyme inhibitors.
- 37. Determine the effects of angiotensine-converting enzyme inhibitors.
- 38. Determine the side effects of angiotensine-converting enzyme inhibitors.
- 39. Determine the particularities of the antihypertensive effect of angiotensin receptor blockers.
- 40. Determine the drugs used in emergencies and hypertensive crises.
- 41. Determine the particularities of use of alpha-adrenomimetics as antihypotensive agents.
- 42. Determine the specifics of the use of alpha-beta adrenomimetics as antihypotensives.
- 43. Determine the pharmacodynamic peculiarities of dopaminomimetics.
- 44. Determine the indications of dopaminomimetics.
- 45. Determine the pharmacodynamic effects of isothiourea derivatives as antihypertensives.
- 46. Determine the peculiarities of the antihypotensive action of glucocorticoids.
- 47. Determine the drugs used in arterial hypotension of the hypotonic type.
- 48. Determine the drugs used in arterial hypotension of the hypertonic type.
- 49. Determine the peculiarities of action of loop diuretics.
- 50. Determine the indications for loop diuretics.
- 51. Determine the adverse reactions of loop diuretics.
- 52. Determine the peculiarities of action of thiazide and non-thiazide diuretics.
- 53. Determine the particularities of action of competitive aldosterone antagonists diuretics.
- 54. Determine the peculiarities of the antihypertensive effect of diuretics.
- 55. Determine the pharmacodynamic effects of dextrans 40,70.

Preparations with influence on the Digestive system

- 1. Determine the advantages of capsules with minimicrospheres of pancreatic enzyme drugs.
- 2. Determine the efficacy criteria of pancreatic enzyme preparations.
- 3. Determine the manifestations of the antiulcer effect of H2-histamine blockers.
- 4. Determine the side effects of H2-histamine blockers.
- 5. Determine the manifestations of the antiulcer effect of proton pump inhibitors.
- 6. Determine the side effects of proton pump inhibitors.
- 7. Determine the possible consequences of marked inhibition of gastric secretion by proton pump inhibitors:
- 8. Determine the particular indications of prostaglandin analogues as antiulcer preprations.
- 9. Determine antacids with neutralizing action.

- 10. Determine the therapeutic effects of nonsystemic antacids.
- 11. Determine the adverse reactions of systemic antacids.
- 12. Determine the effects of dopamine-blocking and serotonergic prokinetics.
- 13. Determine the indications for prokinetics.
- 14. Determine the mechanisms of action of activated charcoal as an antiflatulent.
- 15. Determine the indications for bulk laxatives.
- 16. Determine the indications for laxatives by softening the stool.
- 17. Determine the indications for osmotic purgatives.
- 18. Determine the indications for irritating purgatives with action on the large intestine.
- 19. Determine the particular indications of serotonin antagonists as antivomitives.
- 20. Determine the antiemetics for the treatment of patients with motion sickness.
- 21. Determine the antiemetics that can increase the duration of the QT interval and carry the risk of cardiotoxic reactions:
- 22. Determine the particularities of the antidiarrheal effect of opioids.
- 23. Determine the effects of silymarin.
- 24. Determine the indications of silymarin.
- 25. Determine the advantages of clinical use of silymarin.
- 26. Determine the indications of ademetionine.
- 27. Determine the advantages of clinical use of ademetionine.
- 28. Determine the early effects of the clinical use of ursodeoxycholic acid.
- 29. Determine the advantages of clinical use of ursodeoxycholic acid.
- 30. Determine the pharmacodynamic peculiarities of entomological preparations as hepatoprotectors.

Antibiotics and Chemotherapeutics with diverse chemical structure

- 1. Determine the peculiarities of the spectrum of action for semisynthetic aminopenicillins.
- 2. Determine the peculiarities of the spectrum of action for ureidopenicillins.
- 3. Determine the pharmacokinetic characteristics of natural penicillins.
- 4. Determine the characteristic side effects of penicillins.
- 5. Determine the V-th generation of cephalosporins.
- 6. Determine the peculiarities of the spectrum of action of cephalosporins from III generation.
- 7. Determine the peculiarities of the spectrum of action of cephalosporins from II generation.
- 8. Determine the peculiarities of the spectrum of action of cephalosporins from IV generation.
- 9. Determine the adverse effects of cephalosporins.
- 10. Determine the peculiarities of the spectrum of action for aminoglycosides.
- 11.Determine the characteristic adverse reactions of aminoglycosides.
- 12.Determine the pharmacokinetic peculiarities of aminoglycosides.
- 13.Determine the specific indication for lincosamides.
- 14.Determine the peculiarities of the action spectrum of glycopeptides.
- 15.Determine the characteristic adverse reactions of tetracyclines.
- 16.Determine the peculiarities of the spectrum of action of polymyxins.
- 17.Determine the characteristic adverse reactions of polymyxins.
- 18.Determine the characteristic adverse reaction of lincosamides.
- 19.Determine the specific indications for chloramphenicol.
- 20.Determine the most rational combination of antibiotic groups.
- 21.Determine the specific indication or indications of nitroimidazole derivatives.

22. Determine the antimicrobial groups of choice in the treatment of infections produced by *B*. *fragilis*.

- 23. Determine the components of combined systemic sulfonamides.
- 24.Determine the indication or indications of sulfonamides azocompounds.

- 25.Determine the adverse reactions of sulfonamides.
- 26. Determine the fluoroquinolones active against Mycobacterium tuberculosis.
- 27. Determine the peculiarities of the spectrum of action of fluoroquinolones.
- 28. Determine the characteristic side effects of fluoroquinolones.
- 29. Determine the adverse reaction of nitroimidazole derivatives.
- 30. Determine the peculiarities of the spectrum of action of oxazolidinediones.

Preparations with influence on the CNS

- 1. Determine the groups of sedative drugs.
- 2. Determine the indication or indications of sedative drugs.
- 3. Determine long-acting anxiolytic or anxiolytics.
- 4. Determine the manifestations of the anxiolytic effect of benzodiazepines.
- 5. Determine the pharmacodynamic effects of anxiolytics.
- 6. Determine the indications of anxiolytics.
- 7. Determine the side effects of anxiolytics.
- 8. Determine groups of antipsychotics (neuroleptics) according to the clinical spectrum.
- 9. Determine the peculiarities of the mechanism of action of antipsychotics.
- 10. Determine the effects of antipsychotics.
- 11. Determine the manifestations of the psychosedative effect of antipsychotics.
- 12. Determine the manifestations of the antipsychotic effect of antipsychotics.
- 13. Determine the indications of antipsychotics in psychiatry.
- 14. Determine the side effects of antipsychotics on CNS
- 15. Determine endocrine side effects of antipsychotics.
- 16. Determine cardiovascular side effects of antipsychotics.
- 17. Determine digestive side effects of antipsychotics.
- 18. Determine the clinical manifestations of the antidepressant effect of antidepressant drugs.
- 19. Determine the pharmacodynamic effects of antidepressants.
- 20. Determine the effects of nootropics.
- 21. Determine the indications of nootropic drugs.
- 22. Determine the pharmacodynamic effects of CNS stimulants from the phenylalkylamines group
- 23. Determine the adverse reactions of CNS stimulants from from the phenylalkylamines group
- 24. Determine the manifestations of the psychostimulant effect of methylxanthines
- 25. Determine the indications of CNS stimulants from methylxanthines group.

Analgesic and anti-inflammatory preparations

- 1. Select selective nonsteroidal anti-inflammatory drugs.
- 2. Select the pharmacological effects of NSAIDs.
- 3. Select the indications of NSAIDs.
- 4. Select the side effects of NSAIDs.
- 5. Select the glucocorticoid with the longest duration of action
- 6. Determine the peculiarities of the anti-shock effect of glucocorticoids
- 7. Select the clinical effects on CNS of opioid analgesics.
- 8. Select the indications of opioid analgesics.
- 9. Select the effects of opioid analgesics on the digestive and urinary tract
- 10. Select the effects of opioid analgesics on the respiratory and cardiovascular systems
- 11. Select the CNS side effects of opioid analgesics.
- 12. Select the particularities of the analgesic effect of paracetamol.
- 13. Select the particularities of the analgesic effect of tramadol.
- 14. Select the mechanisms of action of peripherally acting analgesics
- 15. Select the groups of peripherally acting analgesic drugs.

Hormonal preparations of the thyroid gland, antidiabetics and glucocorticoids

- 1. Determine the time to development of the stable clinical effect of levothyroxine.
- 2. Determine the indications of hormonal drugs of the thyroid gland:
- 3. Determine the dosing principles of thyroid gland preparations:
- 4. Determine the pharmacokinetic peculiarities of thyroid drugs:
- 5. Determine the indications of thioamides as antithyroid drugs
- 6. Determine the side effects of antithyroid thioamides:
- 7. Determine the indications of iodine drugs as antithyroid:
- 8. Determine rapid-acting insulin analogues with short duration of action:
- 9. Determine the slow-acting insulin analogues with long duration of action:
- 10. Determine the clinical manifestations of hypoglycemia in case of insulin overdose:
- 11. Determine the dosing principles of insulin drugs:
- 12. Determine the particularities of the hypoglycemic effect of biguanides:
- 13. Determine the particularitie of the hypoglycemic effect of DPP-IV inhibitors:
- 14. Determine the particularities of the hypoglycemic effect of GLP-1 receptor agonists:

15. Determine the particularities of the hypoglycemic effect of sodium-glucose cotransporter-2 inhibitors:

16. Determine the glucocorticoid with the greatest activity (potency):

17. Determine the characteristics of the non-genomic mechanism of action of glucocorticoids:

- 18. Determine the glucocorticoid with the most marked non-genomic mechanism of action:
- 19. Determine the peculiarities of the anti-shock effect of glucocorticoids:
- 20. Determine the adverse reactions of glucocorticoids.